This report evaluates the clinical utility for use of cell-free DNA (cfDNA) screening for fetal trisomy 21, 18, and 13 in high-risk women with singleton or multiple gestation pregnancies. Populations at high risk for aneuploidy include women with advanced maternal age; parental Robertsonian translocation involving chromosome 21 or 13; a previous pregnancy with a trisomy; ultrasound findings associated with an increased risk for trisomy 21, 18, or 13; and/or a positive alternate aneuploidy screening test.
If you have a Hayes login, click here to view the full report on the Knowledge Center.